🇺🇸 FDA
Pipeline program

infusion of MYOCET

RB 12.032 - MYLY

Phase 2 small_molecule terminated

Quick answer

infusion of MYOCET for Cerebral Lymphoma B Cell Refractory is a Phase 2 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Cerebral Lymphoma B Cell Refractory
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials